证券代码：301408 证券简称：华人健康 公告编号：2025-069 安徽华人健康医药股份有限公司 关于使用自有资金支付募投项目部分款项并以募集 资金等额置换的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 安徽华人健康医药股份有限公司（以下简称"公司"或"华人健康"）于 2025 年 10 月 24 日召开第五届董事会第十三次会议，审议通过了《关于使用自 有资金支付募投项目部分款项并以募集资金等额置换的议案》，同意公司在募集 资金投资项目实施期间，在不影响募投项目正常实施的前提下，使用自有资金支 付募投项目部分款项，后续以募集资金等额置换，定期从募集资金专户划转等额 资金至公司自有资金账户，该部分等额置换资金视同募投项目使用资金，上述事 项无需提交公司股东会审议。现将相关事项公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意安徽华人健康医药股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]2406 号）的同意注册，公司获准 向社会公众发行人民币普通股 A 股 6,001.00 万股，每股面值人民币 1 元。截至 202 ...

关于2025年前三季度计提资产减值准备的公告 证券代码：301408 证券简称：华人健康 公告编号：2025-070 安徽华人健康医药股份有限公司 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在 任何虚假记载、误导性陈述或者重大遗漏。 一、本次计提资产减值损失情况概述 （一）计提资产减值准备的原因 为客观、真实、准确地反映公司资产和财务状况，基于谨慎性原则，根据《 企业会计准则》和会计政策的相关规定，安徽华人健康医药股份有限公司（以下 简称"公司"）对截至2025年9月30日合并报表范围内的应收账款、其他应收款、 存货进行了减值测试，并根据减值测试结果计提了相应的减值准备。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第2号——创业板上市公司规范运作》《公司章程》等相关规定，公 司本次计提资产减值准备无需提交公司董事会及股东会审议。 （二）本次资产减值准备的范围和金额 （一）应收账款 公司对应收账款的预期信用损失的确定方法及会计处理方法具体详见公司 《2025年半年度报告》第八节财务报告之"五、重要会计政策及会计估计—11、 金融工具"的"6.金融工具减值"、 ...

安徽华人健康医药股份有限公司 第五届董事会第十三次会议决议公告 证券代码：301408 证券简称：华人健康 公告编号：2025-071 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 安徽华人健康医药股份有限公司（以下简称"公司"）第五届董事会第十三 次会议已于 2025 年 10 月 21 日以书面、邮件送达形式发出通知，并于 2025 年 10 月 24 日在公司总部 A1 栋 1501 会议室以现场结合通讯的方式举行，本次会议 应到董事 9 名，实到董事 9 名，其中董事鲁勖、殷俊、刘亮、程谋以通讯表决方 式出席。本次会议由公司董事长何家乐先生召集和主持，公司高级管理人员列席 了会议。本次会议的召集和召开符合相关法律法规及《公司章程》的规定，做出 的决议合法有效。 二、董事会会议审议情况 本次会议审议并通过如下议案： 1、审议通过《关于公司<2025 年第三季度报告>的议案》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2025 年第三季度报告》（公告编号：2025-068）。 2、审议通过《关于 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥1,388,559,655.82, representing a 26.02% increase year-over-year[5] - Net profit attributable to shareholders was ¥52,983,487.04, up 51.56% compared to the same period last year[5] - The basic earnings per share (EPS) increased by 51.60% to ¥0.1325[5] - The company reported a 19.06% increase in revenue for the year-to-date period, totaling ¥3,892,464,110.99[9] - Total operating revenue for the current period reached ¥3,892,464,110.99, an increase of 19.0% compared to ¥3,269,282,916.66 in the previous period[17] - Net profit for the current period was ¥171,391,855.81, representing a 47.8% increase from ¥115,866,292.21 in the previous period[18] - The total comprehensive income for the current period was ¥172,955,454.44, an increase from ¥116,167,189.21 in the prior period, reflecting strong overall performance[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,368,961,609.98, reflecting an 11.20% increase from the end of the previous year[5] - The company's total assets increased to ¥5,368,961,609.98, up from ¥4,828,108,351.67, reflecting a growth of 11.2%[17] - Total liabilities rose to ¥3,208,878,911.48, compared to ¥2,767,673,601.70, marking an increase of 15.9%[17] - The company’s total liabilities increased, with accounts payable rising by 84.93% to ¥604,765,667.15, attributed to increased inventory and acquisitions[9] - The equity attributable to shareholders of the parent company reached ¥2,096,021,280.80, up from ¥2,005,289,910.33, a growth of 4.5%[17] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥589,977,142.98, up 49.80%[5] - Cash inflow from operating activities totaled ¥3,942,292,569.80, up from ¥3,498,385,903.66, indicating a year-over-year increase of about 12.7%[19] - Net cash flow from operating activities reached ¥589,977,142.98, compared to ¥393,835,456.88 in the previous period, reflecting a growth of approximately 50%[19] - Cash outflow for investment activities was ¥2,164,027,213.18, significantly higher than ¥1,212,534,520.06 from the previous year, resulting in a net cash flow from investment activities of -¥650,893,558.76[20] - Cash inflow from financing activities was ¥514,448,065.00, down from ¥676,175,143.34, leading to a net cash flow from financing activities of -¥54,262,128.84[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,098[11] - The largest shareholder, He Jiale, holds 50.12% of shares, totaling 200,493,326 shares, with 51,000,000 shares pledged[11] Investment and Expenses - Operating costs rose by 17.57% to ¥2,597,540,141.10, driven by increased sales revenue[10] - Research and development expenses for the current period were ¥22,553,167.86, slightly up from ¥21,099,674.53, indicating a focus on innovation[17] - The company experienced a significant increase in investment income, which rose by 263.54% to ¥4,548,916.76 due to increased bank wealth management purchases[10] - The company reported an investment income of ¥4,548,916.76, compared to ¥1,251,299.74 in the previous period, showing significant improvement[18] Current Assets and Inventory - The company’s cash and cash equivalents decreased from ¥999,693,750.44 to ¥780,713,180.51, a decline of approximately 21.9%[15] - Accounts receivable increased from ¥454,170,194.23 to ¥536,525,781.59, representing an increase of about 18.2%[15] - Inventory rose significantly from ¥863,841,347.62 to ¥1,029,783,710.68, marking an increase of approximately 19.2%[15] - The total amount of current assets is ¥2,708,150,834.44, compared to ¥2,597,385,352.74 at the beginning of the period, an increase of approximately 4.3%[15] Other Information - The company has no preferred shareholders as of the reporting period[13] - The company has no long-term receivables or long-term equity investments reported[15] - The third quarter financial report was not audited, indicating that the figures may be subject to adjustments[21]

核查意见 华泰联合证券有限责任公司关于 安徽华人健康医药股份有限公司使用自有资金支付募投项 目部分款项并以募集资金等额置换的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为安徽华人健康医药股份有限公司（以下简称"华人健康"或"公司"）首次公 开发行股票并在创业板上市持续督导阶段的保荐人，根据《证券发行上市保荐业 务管理办法》《上市公司募集资金监管规则》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》及《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等有关 规定，对华人健康使用自有资金支付募投项目部分款项并以募集资金等额置换事 项进行了核查，具体核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意安徽华人健康医药股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]2406 号）同意注册，公司获准向社 会公众发行人民币普通股 A 股 6,001.00 万股，每股面值人民币 1 元。截至 2023 年 3 月 1 日止，本公司已向社会公众发行人民币普通股 A 股 6,001 ...

Core Insights - The company reported a revenue of 1.389 billion yuan for Q3 2025, representing a year-on-year growth of 26.02% [1] - The net profit attributable to shareholders for Q3 2025 was 52.9835 million yuan, showing a year-on-year increase of 51.56% [1] - Basic earnings per share for Q3 2025 were 0.1325 yuan [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 3.892 billion yuan, which is a 19.06% increase compared to the same period last year [1] - The net profit attributable to shareholders for the first three quarters was 157 million yuan, reflecting a year-on-year growth of 45.21% [1] - Basic earnings per share for the first three quarters were 0.3918 yuan [1]

Group 1 - The core point of the article is that Huaren Health announced the receipt of a drug registration application acceptance notice from the National Medical Products Administration for Dapagliflozin tablets [2] Group 2 - The announcement was made on the evening of October 23, indicating a significant regulatory milestone for the company [2] - The drug is developed by Jiangsu Shenhua Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huaren Health [2]

Core Viewpoint - The company, Huaren Health, has established a strategic partnership with iFlytek's medical division to enhance professional service efficiency in pharmacy settings and address user health needs through the launch of the "Pharmacy AI Health Assistant" [1] Group 1 - The collaboration aims to improve the efficiency of professional services in pharmacies [1] - The initiative aligns with the company's strategy to develop a smart pharmaceutical service ecosystem and strengthen terminal professional capabilities [1] - This move is consistent with the company's ongoing efforts in research and digital intelligence construction [1]

证券代码：301408 证券简称：华人健康 公告编号：2025-067 安徽华人健康医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 近日，安徽华人健康医药股份有限公司（以下简称"公司"）全资子公司江 苏神华药业有限公司收到国家药品监督管理局下发的达格列净片药品注册上市 许可申请《受理通知书》。现将相关情况公告如下： 一、《受理通知书》主要内容 申请事项：境内生产药品注册上市许可 四、报备文件 1、《达格列净片受理通知书》。 特此公告。 规格：10mg（以 C₂₁H₂₅ClO₆计） 受理说明：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 受理号：CYHS250***2 二、达格列净片的相关情况 达格列净片是一种治疗 2 型糖尿病的新型口服降糖药物，是全球首款获批上 市的钠-葡萄糖协同转运蛋白-2（SGLT-2）抑制剂。达格列净选择性和强效地抑 制 SGLT-2，阻断近曲小管对葡萄糖的重吸收，可以使多余的葡萄糖通过尿液被 排出体外，从而在不增加胰岛素分泌的情況下改善血 ...

Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is actively expanding its presence in the health sector for the elderly, focusing on chronic disease management and product development tailored to the needs of older adults [2][3]. Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and went public on March 1, 2023. The company primarily engages in pharmaceutical agency, retail, and terminal procurement, with its main revenue derived from traditional Chinese and Western medicine, accounting for 97.60% of total revenue [7]. - As of June 30, 2023, the company had 26,100 shareholders, an increase of 45.15% from the previous period, with an average of 5,725 circulating shares per person, a decrease of 31.10% [8]. Financial Performance - For the first half of 2025, the company reported a revenue of 2.504 billion yuan, representing a year-on-year growth of 15.52%. The net profit attributable to shareholders was 104 million yuan, up 42.17% compared to the previous year [8]. Market Position and Strategy - The company has established a significant presence on major e-commerce platforms in China, including JD.com, Pinduoduo, and Meituan, in addition to Alibaba's Tmall and Ele.me [2]. - The company is focusing on the "Silver Health" sector by providing chronic disease training and services through pharmacies, and developing a series of products aimed at common health issues among the elderly [2][3]. Shareholder Structure - Alibaba Health is the second-largest shareholder, holding 7.51% of the company, and there are collaborations with various Alibaba platforms, including Alipay and Tmall [3]. Investment and Innovation - The company's subsidiary, Anhui Zhengyao Pharmaceutical Technology Co., Ltd., focuses on innovative drugs and high-end generics, with 22 research projects in progress as of June 30, 2023 [3].